A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Inclusion Criteria:

- Adult patient, >/= 18 years of age

- Histologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer
(NSCLC)

- No prior treatment for unresectable Stage IIIB or IV NSCLC

- Measurable radiographic evidence of disease according to RECIST v1.1

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

- Prior exposure to agents targeting either the Hepatocyte Growth Factor (HGF) or MET
pathway

- Exposure to an investigational or marketed agent that can act by EGFR inhibition

- Pleural effusion, pericardial fluid, or ascites requiring drainage every other week
or more frequently

- Brain metastasis or spinal cord compression not definitively treated with surgery
and/or radiation, or previously diagnosed and treated central nervous system (CNS)
metastases or spinal cord compression without evidence of clinically stable disease
for >/=4 days. Note: Patients with treated CNS metastases who are asymptomatic and on
a stable dose of corticosteroids for >/= 14 days prior to randomization are eligible.

- History of another malignancy in the previous 5 years, unless cured by surgery alone
and continuously disease-free

- Radiographically evident interstitial lung disease , concurrent infection, or a
history of any of these conditions

- Inadequate hematologic, biochemical, and organ function

- Pregnant or lactating women

- Life expectancy of < 12 weeks

- Receipt of an investigational drug within 28 days prior to initiation of study
treatment